Drug intelligence / Profile preview

exemestane + ganitumab

Development stage: Discontinued
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of exemestane, an aromatase inhibitor, and ganitumab, a fully human monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R). This combination was investigated for the treatment of hormone-receptor-positive breast cancer, particularly in postmenopausal women with advanced disease. The rationale was to enhance endocrine therapy efficacy by simultaneously targeting the IGF-1R signaling pathway, which is involved in cancer cell survival and proliferation.

Other names: ganitumab + exemestane

Targets

IGF-1R (Insulin-like growth factor 1 receptor)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on exemestane + ganitumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on exemestane + ganitumab.

Explore the full profile